Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroids plus cyclosporin in idiopathic membranous nephropathy
NCT02173106Phase 2
Key facts
- Status
- Unknown
- Start
- Jun 2014
- Primary completion
- Dec 2016
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Peptides, Orthosteric Ligands
- Conditions
- idiopathic membranous nephropathy (IMN)
01
Overview
Phase 2, randomised, open-label trial of methylprednisolone and cyclosporine in idiopathic membranous nephropathy (IMN), sponsored by Sun Yat-sen University. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 14-75 with biopsy-proven idiopathic membranous nephropathy, significant proteinuria (>3.5g/24h) or hypoalbuminemia (<30g/l), and preserved renal function (eGFR >= 40 ml/min/1.73m2).
04
Registry description
This prospective, randomized, controlled, multicenter clinical trial will evaluate Opportunity, Validity and Security of Steroids Plus Cyclosporin therapy for patients of Idiopathic Membranous Nephropathy.
Beyond the preview
Go deeper on NCT02173106.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173106.